Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thoratec Expands Circulatory Support Biz With Levitronix Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Thoratec will broaden its mechanical circulatory support portfolio through the purchase of Levitronix’s acute surgical support offerings for up to $150 million.

You may also be interested in...



Thoratec Goes Back To The Future With CEO Appointment

D. Keith Grossman, who led the LVAD maker from 1996 to 2006, has returned as CEO following the resignation of Gary Burbach. The company has been reporting declining sales of its franchise HeartMate II LVAD system.

Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth

“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.

Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012

Thoratec plans to start a clinical trial at the end of 2012 for its next-generation HeartMate III left ventricular assist device with a magnetically levitated rotor designed to help reduce the risk of pump-related clots, bleeding and strokes.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel